Johnson & Johnson's RYBREVANT and LAZCLUZE Combination Significantly Extends Survival in EGFR-Mutated Lung Cancer Patients, Surpassing Osimertinib

Johnson & Johnson announced on March 26, 2025, that its combination therapy of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) delivered a significant and unprecedented overall survival benefit compared to osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The findings, presented at the 2025 European Lung Cancer Congress, came from the Phase 3 MARIPOSA trial.

At a median follow-up of 37.8 months, the median overall survival for the RYBREVANT plus LAZCLUZE group had not yet been reached, with projections indicating a survival extension of over one year compared to osimertinib, whose median OS was 36.7 months. At the 3.5-year mark, 56 percent of patients receiving the combination were still alive, compared to 44 percent on osimertinib. The hazard ratio was 0.75, with a nominal p-value under 0.005.

The combination also showed benefits across several secondary endpoints, including intracranial progression-free survival, duration of response, overall response rate, and notably, time to symptomatic progression—43.6 months versus 29.3 months with osimertinib. This underscores not only survival improvement but prolonged quality of life.

Safety data showed no new concerns, with adverse events consistent with prior findings. Most occurred early in treatment. The company noted that proactive management in the first four months, including prophylactic measures, could help reduce the risk of skin reactions, infusion-related events, and venous thromboembolism.

RYBREVANT plus LAZCLUZE is already approved in the US, Europe, and other regions for first-line treatment of EGFR-mutated NSCLC. The overall survival data will be submitted to global health authorities for potential updates to labeling and treatment guidelines.

The MARIPOSA study enrolled 1,074 patients and continues to track additional endpoints. Johnson & Johnson emphasized that the data marks a potential shift in the standard of care, offering new hope for patients facing EGFR-mutant NSCLC.